Compare PAYO & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYO | HRMY |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | 2540 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | N/A | 2020 |
| Metric | PAYO | HRMY |
|---|---|---|
| Price | $7.11 | $38.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $7.69 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 4.2M | 890.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 1.84 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $7.15 | $19.75 |
| Revenue Next Year | $10.28 | $12.88 |
| P/E Ratio | $30.36 | ★ $21.06 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $4.08 | $25.52 |
| 52 Week High | $7.18 | $40.87 |
| Indicator | PAYO | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 62.77 | 63.35 |
| Support Level | $7.07 | $37.12 |
| Resistance Level | $7.15 | $39.07 |
| Average True Range (ATR) | 0.04 | 1.60 |
| MACD | -0.04 | 0.28 |
| Stochastic Oscillator | 22.22 | 82.13 |
Payoneer Global Inc is a financial technology company that enables small and medium-sized businesses (SMBs) to grow internationally through its diversified cross-border payments platform. It connects businesses, professionals, countries, and currencies, reducing the complexity of commerce and enabling customers to pay and get paid as easily as locally. The company offers a financial stack that includes cross-border AR/AP capabilities, funds management, working capital solutions, multicurrency accounts, and workforce management services. Its fully hosted platform provides multiple payment options with minimal integration, along with back-office functions and customer support. The company operates in Israel, the United States, and other countries.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.